Literature DB >> 16760655

CDK2 is required by MYC to induce apoptosis.

Debabrita Deb-Basu1, Eiman Aleem, Philipp Kaldis, Dean W Felsher.   

Abstract

Depending upon the cellular and physiologic context, the overexpression of the MYC proto-oncogene results in rapid cell growth, proliferation, induction of apoptosis and/or proliferative arrest. What determines the precise consequences upon MYC activation is not clear. We have found that cyclin-dependent kinase 2 (CDK2) is required by MYC to induce apoptosis. MYC-induced apoptosis was suppressed in mouse embryonic fibroblasts (MEF) knocked out for Cdk2 or normal human fibroblasts (NHF) upon expression of the CDK2 inhibitor p27 or treated with RNAi directed at CDK2. Knockout of Cdk2 did not prevent MYC from inducing p53 and Bim. The inhibition of CDK2 did not prevent apoptosis induced by the DNA damaging agent etoposide. Our results surprisingly suggest that CDK2 defines whether MYC induction causes apoptosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16760655     DOI: 10.4161/cc.5.12.2859

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  10 in total

Review 1.  c-Myc induction of programmed cell death may contribute to carcinogenesis: a perspective inspired by several concepts of chemical carcinogenesis.

Authors:  Chenguang Wang; Yanhong Tai; Michael P Lisanti; D Joshua Liao
Journal:  Cancer Biol Ther       Date:  2011-04-01       Impact factor: 4.742

2.  Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis.

Authors:  Subbareddy Maddika; Sudharsana Rao Ande; Emilia Wiechec; Lise Lotte Hansen; Sebastian Wesselborg; Marek Los
Journal:  J Cell Sci       Date:  2008-04-01       Impact factor: 5.285

3.  Myc and a Cdk2 senescence switch.

Authors:  Jan van Riggelen; Dean W Felsher
Journal:  Nat Cell Biol       Date:  2010-01       Impact factor: 28.824

4.  Cdk2 suppresses cellular senescence induced by the c-myc oncogene.

Authors:  Stefano Campaner; Mirko Doni; Per Hydbring; Alessandro Verrecchia; Lucia Bianchi; Domenico Sardella; Thomas Schleker; Daniele Perna; Susanna Tronnersjö; Matilde Murga; Oscar Fernandez-Capetillo; Mariano Barbacid; Lars-Gunnar Larsson; Bruno Amati
Journal:  Nat Cell Biol       Date:  2009-12-13       Impact factor: 28.824

5.  ATM kinase is a master switch for the Delta Np63 alpha phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damage.

Authors:  Yiping Huang; Tanusree Sen; Jatin Nagpal; Sunil Upadhyay; Barry Trink; Edward Ratovitski; David Sidransky
Journal:  Cell Cycle       Date:  2008-09-15       Impact factor: 4.534

6.  Cdk2 plays a critical role in hepatocyte cell cycle progression and survival in the setting of cyclin D1 expression in vivo.

Authors:  Eric A Hanse; Christopher J Nelsen; Melissa M Goggin; Chelsea K Anttila; Lisa K Mullany; Cyril Berthet; Philipp Kaldis; Gretchen S Crary; Ryoko Kuriyama; Jeffrey H Albrecht
Journal:  Cell Cycle       Date:  2009-09-08       Impact factor: 4.534

7.  Cdk2 deficiency decreases ras/CDK4-dependent malignant progression, but not myc-induced tumorigenesis.

Authors:  Everardo Macias; Yongbaek Kim; Paula L Miliani de Marval; Andres Klein-Szanto; Marcelo L Rodriguez-Puebla
Journal:  Cancer Res       Date:  2007-10-15       Impact factor: 12.701

Review 8.  MYC and the control of DNA replication.

Authors:  David Dominguez-Sola; Jean Gautier
Journal:  Cold Spring Harb Perspect Med       Date:  2014-06-02       Impact factor: 6.915

Review 9.  Pemphigus autoimmunity: hypotheses and realities.

Authors:  Sergei A Grando
Journal:  Autoimmunity       Date:  2011-09-23       Impact factor: 2.815

10.  Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors.

Authors:  Lynsey Vaughan; Paul A Clarke; Karen Barker; Yvan Chanthery; Clay W Gustafson; Elizabeth Tucker; Jane Renshaw; Florence Raynaud; Xiaodun Li; Rosemary Burke; Yann Jamin; Simon P Robinson; Andrew Pearson; Michel Maira; William A Weiss; Paul Workman; Louis Chesler
Journal:  Oncotarget       Date:  2016-09-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.